In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Market Intelligence

Set Alert for Market Intelligence

Deals In Depth: August 2018

In a partnership worth up to $5 billion, Affimed and Genentech will discovery innate immune cell immunotherapies for solid and hematological tumors. Emergent BioSolutions did two acquisitions, one in infectious disease (PaxVax) and the other in opioid overdose (Adapt Pharma). Biopharma financing reached nearly $4 billion, while device fundraising was just over $1 billion.

BioPharmaceutical Medical Device Deals
Advertisement

Latest From Market Intelligence

Deals Shaping The Medical Industry, January 2019

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2018.

Deals Market Intelligence

2018’s Top Biopharma Deal-makers

Even though 2018 did not feature the big influx of biopharma M&A that was expected, there were still encouraging signs that major advancements and breakthroughs in the biotech industry attract buy-outs. Cancer-focused companies and oncology assets again drove volume in alliances and financing transactions.

Deals Market Intelligence

Conflict Management Strategies: Protect Your Medtech Company Against Three Common Contract Failures

A company’s contracts of today drive its income of tomorrow – but also its disputes. Dorothee Schramm, a partner at Sidley Austin who specializes in international commercial disputes, provides tips on how to avoid partnership conflicts.

Market Intelligence M & A

Medtech Business Models: All Razor And No Blades – Is “Big Iron” Back In Vogue?

The conventional wisdom in the medtech industry is to pursue the “razor-razor blade” business model, as each placement of capital equipment generates a lucrative annuity of recurring revenues from disposables. The corollary to this conventional wisdom is that so-called “big iron” is to be avoided as, in sharp contrast, it suffers from greater early cash requirements and longer sales cycles that create difficulties forecasting quarterly revenues, and provides no annuities. But that view is no longer the only one that counts, Health Advances CEO Mark Speers argues.

Market Intelligence Business Strategies

Deals Shaping The Medical Industry, December 2018

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in November 2018.

Deals BioPharmaceutical

Device/Diagnostics Quarterly Dealmaking Statistics, Q3 2018

Third quarter device financing totaled $2.6 billion, a 24% decrease from the $3.4 billion brought in during Q2. The change partially stems from a sharp decline in debt financing. During the third quarter, debt raises brought in $258 million, just 10% of the Q3 total, while in the previous quarter, aggregate debt (at $947 million) represented 28% of the financing total.

Deals Analysis
See All
UsernamePublicRestriction

Register